KR20240147980A - 신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 - Google Patents

신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 Download PDF

Info

Publication number
KR20240147980A
KR20240147980A KR1020247024332A KR20247024332A KR20240147980A KR 20240147980 A KR20240147980 A KR 20240147980A KR 1020247024332 A KR1020247024332 A KR 1020247024332A KR 20247024332 A KR20247024332 A KR 20247024332A KR 20240147980 A KR20240147980 A KR 20240147980A
Authority
KR
South Korea
Prior art keywords
csf
patient
disease
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024332A
Other languages
English (en)
Korean (ko)
Inventor
에드윈 록
일라 조쉬
티모시 보이드
Original Assignee
파트너 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파트너 테라퓨틱스 인코포레이티드 filed Critical 파트너 테라퓨틱스 인코포레이티드
Publication of KR20240147980A publication Critical patent/KR20240147980A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247024332A 2022-02-11 2023-02-10 신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 Pending KR20240147980A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309220P 2022-02-11 2022-02-11
US63/309,220 2022-02-11
PCT/US2023/062374 WO2023154855A2 (en) 2022-02-11 2023-02-10 Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Publications (1)

Publication Number Publication Date
KR20240147980A true KR20240147980A (ko) 2024-10-10

Family

ID=87565120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024332A Pending KR20240147980A (ko) 2022-02-11 2023-02-10 신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료

Country Status (8)

Country Link
US (1) US20250134959A1 (enExample)
EP (1) EP4475874A4 (enExample)
JP (1) JP2025508308A (enExample)
KR (1) KR20240147980A (enExample)
CN (1) CN118660715A (enExample)
AU (1) AU2023219770A1 (enExample)
CA (1) CA3242855A1 (enExample)
WO (1) WO2023154855A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235795A2 (en) * 2022-06-01 2023-12-07 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
WO2025168003A1 (zh) * 2024-02-06 2025-08-14 上海市第四人民医院 一种治疗神经退行性疾病的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2017185085A1 (en) * 2016-04-22 2017-10-26 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP4103618A4 (en) * 2020-02-12 2024-05-01 The Scripps Research Institute LONG-ACTING GM-CSF AND METHODS OF USE

Also Published As

Publication number Publication date
CA3242855A1 (en) 2023-08-17
WO2023154855A2 (en) 2023-08-17
AU2023219770A1 (en) 2024-08-22
CN118660715A (zh) 2024-09-17
US20250134959A1 (en) 2025-05-01
EP4475874A4 (en) 2026-05-13
JP2025508308A (ja) 2025-03-26
EP4475874A2 (en) 2024-12-18
WO2023154855A3 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
CN110461871B (zh) 白蛋白结合结构域融合蛋白
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
JP7678802B2 (ja) Siglec-9ECD融合分子及びその使用方法
ITRM940794A1 (it) Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
US20250134959A1 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
Silverstein et al. CD36-TSP-HRGP interactions in the regulation of angiogenesis
US20070149439A1 (en) Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
JP2006515161A (ja) エリスロポエチンのt細胞エピトープ
EP3917958A1 (en) Treatment of neurotoxicity and / or cytokine release syndrome
KR20080060226A (ko) 신경 질환의 치료 및/또는 예방을 위한 sdf-1의 용도
KR20040008177A (ko) 신경 사 단백질 세그먼트를 사용하여 세포 사멸을억제하는 방법
US20170137483A1 (en) Use of epo-derived peptide fragments for the treatment of inflammatory diseases
CN118043672A (zh) 帕金森病的生物标志物
US20240361339A1 (en) Biomarkers for parkinson's disease
EP1740199B1 (en) Il6r/il6 chimera for therapy of chemotherapy-induced peripheral neuropathy
JP2007534746A (ja) 化学療法誘発性ニューロパシーの治療または予防のためのil−6
JP2003509472A (ja) M3ポリペプチドの治療的使用
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
CA2938366C (en) New pharmaceutical compositions and their use for the treatment of autoimmune disorders
WO2023235795A2 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
AU2011203356B2 (en) IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament
KR20040029968A (ko) 신경 사 단백질에 대한 항체를 사용하여 세포 사멸을억제하는 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000